FDA Investigational Drug Export Rule Encourages IND, Requires Certification
Executive Summary
Firms exporting investigational drugs may want to obtain INDs for the products even though the designation is not required, FDA said in a 1proposed rule published in the Federal Register June 19
You may also be interested in...
IND Export Requirements Simplified In FDA Final Rule
A final rule issued by FDA simplifying requirements for investigational new drug exports prohibits transshipment of drugs from a "listed" country to an "unlisted" country where the drug does not have market authorization, but otherwise includes few changes over the proposed rule issued in 2002
IND Export Requirements Simplified In FDA Final Rule
A final rule issued by FDA simplifying requirements for investigational new drug exports prohibits transshipment of drugs from a "listed" country to an "unlisted" country where the drug does not have market authorization, but otherwise includes few changes over the proposed rule issued in 2002
FDA Regulatory Agenda Includes “Complete Response” Rule, E-Drug Listing
A notice of proposed rulemaking for FDA's "complete response" regulation is scheduled for publication in July, according to HHS' semiannual regulatory agenda published in the June 28 Federal Register